A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy
Carregando...
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Citação
EUROPACE, v.20, n.11, p.1813-1818, 2018
Resumo
Aims Cardiac resynchronization therapy (CRT) is an established procedure for patients with heart failure. However, trials evaluating its efficacy did not include patients with chronic Chagas cardiomyopathy (CCC). We aimed to assess the role of CRT in a cohort of patients with CCC. Methods and results This retrospective study compared the outcomes of CCC patients who underwent CRT with those of dilated (DCM) and ischaemic cardiomyopathies (ICM). The primary endpoint was all-cause mortality and the secondary endpoints were the rate of non-advanced New York Heart Association (NYHA) class 12 months after CRT and echocardiographic changes evaluated at least 6 months after CRT. There were 115 patients in the CCC group, 177 with DCM, and 134 with ICM. The annual mortality rates were 25.4%, 10.4%, and 11.3%, respectively (P < 0.001). Multivariate analysis adjusted for potential confounders showed that the CCC group had a two-fold [hazard ratio 2.34 (1.47-3.71), P < 0.001] higher risk of death compared to the DCM group. The rate of non-advanced NYHA class 12 months after CRT was significantly higher in non-CCC groups than in the CCC group (DCM 74.0% vs. ICM 73.9% vs. 56.5%, P < 0.001). Chronic Chagas cardiomyopathy and ICM patients had no improvement in the echocardiographic evaluation, but patients in the DCM group had an increase in left ventricular ejection fraction and a decrease in left ventricular end-diastolic diameter. Conclusion This study showed that CCC patients submitted to CRT have worse prognosis compared to patients with DCM and ICM who undergo CRT. Studies comparing CCC patients with and without CRT are warranted.
Palavras-chave
Cardiac resynchronization therapy, Chagas cardiomyopathy, Prognosis, Heart failure
Referências
- [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33
- Ayub-Ferreira SM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002176
- Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
- Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496
- Curtis AB, 2013, NEW ENGL J MED, V368, P1585, DOI 10.1056/NEJMoa1210356
- de Araujo EF, 2014, REV BRAS CIR CARDIOV, V29, P31, DOI 10.5935/1678-9741.20140008
- Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
- Gierula J, 2013, EUROPACE, V15, P1609, DOI 10.1093/europace/eut148
- Goldenberg I, 2014, NEW ENGL J MED, V352, P1
- Kutyifa V, 2014, CIRC-ARRHYTHMIA ELEC, V7, P645, DOI 10.1161/CIRCEP.113.001299
- Marijon E, 2015, EUR HEART J, V36, P2767, DOI 10.1093/eurheartj/ehv455
- Martinelli Filho M, 2007, ARQ BRAS CARDIOL, V89, pe210, DOI 10.1590/S0066-782X2007001800011
- Martinelli M, 2010, J CARD FAIL, V16, P293, DOI 10.1016/j.cardfail.2009.12.008
- Martinelli M, 2013, AM HEART J, V166, P976, DOI 10.1016/j.ahj.2013.08.027
- Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X
- Rochitte CE, 2005, J AM COLL CARDIOL, V46, P1553, DOI 10.1016/j.jacc.2005.06.067
- Sairaku A, 2016, INT J CARDIOL, V221, P597, DOI 10.1016/j.ijcard.2016.06.338
- Silva Rodrigo Tavares, 2008, Arq Bras Cardiol, V90, P138
- Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540
- Wu KC, 2008, J AM COLL CARDIOL, V51, P2414, DOI 10.1016/j.jacc.2008.03.018